﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Nickan Research Institute</PublisherName>
      <JournalTitle>Journal of Renal Injury Prevention</JournalTitle>
      <Issn>2345-2781</Issn>
      <Volume>12</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2023</Year>
        <Month>12</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>The effects of Portulaca oleracea extract on 24-hour urine indices in patients with renal stone: A double-blind randomized placebo-controlled clinical trial</ArticleTitle>
    <FirstPage>e32240</FirstPage>
    <LastPage>e32240</LastPage>
    <ELocationID EIdType="doi">10.34172/jrip.2023.32240</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Amirhesam</FirstName>
        <LastName>Alirezaei</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0001-9720-6723</Identifier>
      </Author>
      <Author>
        <FirstName>Kimia</FirstName>
        <LastName>Karimi Toudeshki</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0001-7560-7091</Identifier>
      </Author>
      <Author>
        <FirstName>Seyed Behnaz</FirstName>
        <LastName>Nouri</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0003-4146-6336</Identifier>
      </Author>
      <Author>
        <FirstName>Seyed Amirhossein</FirstName>
        <LastName>Fazeli</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-8383-9877</Identifier>
      </Author>
      <Author>
        <FirstName>Firoze</FirstName>
        <LastName>Hatami</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0003-0450-0961</Identifier>
      </Author>
      <Author>
        <FirstName>Amirhossein</FirstName>
        <LastName>Miladipour</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0003-4567-1193</Identifier>
      </Author>
      <Author>
        <FirstName>Seyed Pedram</FirstName>
        <LastName>Montazeri-Ghominezhad</LastName>
        <Identifier Source="ORCID">https://orcid.org/0009-0004-8630-7990</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/jrip.2023.32240</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>04</Month>
        <Day>13</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2023</Year>
        <Month>09</Month>
        <Day>10</Day>
      </PubDate>
    </History>
    <Abstract>Introduction: Portulaca oleracea, or purslane, is a medicinal plant used in traditional medicine, according to its various medical properties, as well as its potential antioxidant and anti-inflammatory properties. Objectives: The present study aimed to investigate the efficacy of P. oleracea powder on 24-hour urine indices in patients with nephrolithiasis and normal kidney function. Patients and Methods: In this randomized clinical trial, eligible patients with nephrolithiasis were randomly assigned to receive P. oleracea or placebo capsules once daily for eight weeks. Twenty-four-hour urine indices, along with serum electrolytes, inflammatory and lipid components were measured, then compared between the two groups at baseline and the end of the trial. Results: A total of 54 patients, including 28 in P. oleracea and 26 in the control groups, were assigned. Their mean age was 42.2±9.8 years; there was no statistically significant difference between the mean age of the P. oleracea and placebo groups (42.1years versus 42.2 years, respectively; P&gt;0.05). After eight weeks, the mean urine citrate level in the Portulaca oleracea subjects (674.82±94.56 mg/24 h) was significantly higher than placebo group subjects (579.19±85.06 mg/24 h; P&lt;0.01). In addition, the mean urine calcium level in the P. oleracea group (176.32±27.40 mg/24 h) was significantly lower compared to the control group (194.26±25.17 mg/24 h; P=0.016). Within the groups, analysis revealed that in subjects in P. oleracea and control groups, mean serum triglyceride (TG) decreased after intervention (P=0.01 and P=0.02, respectively), as well as mean urine citrate level (P&lt;0.01, P=0.01, respectively). Conclusion: The findings show that P. oleracea may be proposed as a medicinal plant that has a preventive effect on kidney stone formation by increasing urine citrate and decreasing urine calcium level. Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trials (identifier: IRCT20170725035305N4; https://en.irct.ir/trial/42388, ethical code; IR.SBMU.MSP. REC.1398.538).</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Portulaca</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Portulaca oleracea</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nephrolithiasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Urine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Kidney calculi</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Urolithiasis</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>